Wanbo Tai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7116283/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cellular and Molecular Immunology, 2020, 17, 613-620.	10.5	1,376
2	Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry. Journal of Virology, 2020, 94, .	3.4	539
3	A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2. Cell Research, 2020, 30, 932-935.	12.0	124
4	Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines. Nature Communications, 2016, 7, 13473.	12.8	106
5	Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2. Antiviral Research, 2020, 179, 104820.	4.1	106
6	Cryo-Electron Microscopy Structure of Porcine Deltacoronavirus Spike Protein in the Prefusion State. Journal of Virology, 2018, 92, .	3.4	101
7	A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. Virology, 2016, 499, 375-382.	2.4	95
8	Vaccines for the prevention against the threat of MERS-CoV. Expert Review of Vaccines, 2016, 15, 1123-1134.	4.4	87
9	Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2 protein-protein interaction. Biophysical Journal, 2021, 120, 1011-1019.	0.5	87
10	A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV. Journal of Virology, 2018, 92, .	3.4	77
11	Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants. Journal of Virology, 2017, 91, .	3.4	69
12	Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen. Vaccine, 2018, 36, 1853-1862.	3.8	62
13	Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection. Human Vaccines and Immunotherapeutics, 2017, 13, 1615-1624.	3.3	50
14	Identification of Novel Natural Products as Effective and Broad-Spectrum Anti-Zika Virus Inhibitors. Viruses, 2019, 11, 1019.	3.3	50
15	Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection. PLoS Pathogens, 2021, 17, e1009897.	4.7	49
16	Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection. Antiviral Research, 2016, 132, 141-148.	4.1	46
17	The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates. ELife, 2021, 10, .	6.0	42
18	Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III. Emerging Microbes and Infections, 2017, 6, 1-11.	6.5	41

Wanbo Tai

#	Article	IF	CITATIONS
19	Critical neutralizing fragment of Zika virus EDIII elicits cross-neutralization and protection against divergent Zika viruses. Emerging Microbes and Infections, 2018, 7, 1-8.	6.5	41
20	Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses. Science China Life Sciences, 2017, 60, 1399-1402.	4.9	33
21	Rational Design of Zika Virus Subunit Vaccine with Enhanced Efficacy. Journal of Virology, 2019, 93, .	3.4	32
22	Enhanced Ability of Oligomeric Nanobodies Targeting MERS Coronavirus Receptor-Binding Domain. Viruses, 2019, 11, 166.	3.3	23
23	Highly conserved M2e and hemagglutinin epitope-based recombinant proteins induce protection against influenza virus infection. Microbes and Infection, 2017, 19, 641-647.	1.9	18
24	A vaccine inducing solely cytotoxic T lymphocytes fully prevents Zika virus infection and fetal damage. Cell Reports, 2021, 35, 109107.	6.4	18
25	Effects of Adjuvants on the Immunogenicity and Efficacy of a Zika Virus Envelope Domain III Subunit Vaccine. Vaccines, 2019, 7, 161.	4.4	16
26	Transfusion-Transmitted Zika Virus Infection in Pregnant Mice Leads to Broad Tissue Tropism With Severe Placental Damage and Fetal Demise. Frontiers in Microbiology, 2019, 10, 29.	3.5	14
27	RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge. Translational Research, 2022, 248, 11-21.	5.0	13
28	Advances in mRNA and other vaccines against MERS-CoV. Translational Research, 2022, 242, 20-37.	5.0	11
29	Development of a ferritin-based nanoparticle vaccine against the SARS-CoV-2 Omicron variant. Signal Transduction and Targeted Therapy, 2022, 7, .	17.1	11
30	The Potency of an Anti-MERS Coronavirus Subunit Vaccine Depends on a Unique Combinatorial Adjuvant Formulation. Vaccines, 2020, 8, 251.	4.4	9
31	A gossypol derivative effectively protects against Zika and dengue virus infection without toxicity. BMC Biology, 2022, 20, .	3.8	3
32	Re-burying Artificially Exposed Surface of Viral Subunit Vaccines Through Oligomerization Enhances Vaccine Efficacy. Frontiers in Cellular and Infection Microbiology, 0, 12, .	3.9	0